[go: up one dir, main page]

DK1765289T3 - Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider - Google Patents

Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider

Info

Publication number
DK1765289T3
DK1765289T3 DK05756461T DK05756461T DK1765289T3 DK 1765289 T3 DK1765289 T3 DK 1765289T3 DK 05756461 T DK05756461 T DK 05756461T DK 05756461 T DK05756461 T DK 05756461T DK 1765289 T3 DK1765289 T3 DK 1765289T3
Authority
DK
Denmark
Prior art keywords
glycolipids
compositions
methods
based adjuvant
adjuvant formulations
Prior art date
Application number
DK05756461T
Other languages
English (en)
Inventor
Jesper Davidsen
Ida Rosenkrands
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1765289(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of DK1765289T3 publication Critical patent/DK1765289T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05756461T 2004-07-07 2005-07-05 Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider DK1765289T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200401070 2004-07-07
PCT/DK2005/000467 WO2006002642A2 (en) 2004-07-07 2005-07-05 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

Publications (1)

Publication Number Publication Date
DK1765289T3 true DK1765289T3 (da) 2008-12-15

Family

ID=34982425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05756461T DK1765289T3 (da) 2004-07-07 2005-07-05 Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider

Country Status (16)

Country Link
EP (1) EP1765289B1 (da)
JP (1) JP4987704B2 (da)
KR (1) KR101275837B1 (da)
CN (1) CN1980638B (da)
AT (1) ATE406874T1 (da)
AU (1) AU2005259685B2 (da)
BR (1) BRPI0512757B8 (da)
CA (1) CA2572985C (da)
DE (1) DE602005009535D1 (da)
DK (1) DK1765289T3 (da)
ES (1) ES2315880T3 (da)
PL (1) PL1765289T3 (da)
PT (1) PT1765289E (da)
SI (1) SI1765289T1 (da)
WO (1) WO2006002642A2 (da)
ZA (1) ZA200701043B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2490024C2 (ru) 2006-06-28 2013-08-20 Статенс Серум Инститьют Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
ES2430206T3 (es) 2006-10-03 2013-11-19 Tekmira Pharmaceuticals Corporation Formulación que contiene lípidos
JP5689314B2 (ja) 2007-06-29 2015-03-25 スタテンス セールム インスティトゥート モノミコリルグリセロール（ｍｍｇ）のアジュバントとしての使用
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
AU2010203451B2 (en) * 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
ES2573427T3 (es) * 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
MX2013000045A (es) * 2010-07-02 2013-02-15 Univ Louisiana State Vacuna contra ehrlichia canis.
US20140112979A1 (en) 2011-07-04 2014-04-24 Statens Serum Institut Methods for producing liposomes
WO2013089151A1 (ja) * 2011-12-12 2013-06-20 協和発酵キリン株式会社 カチオン性脂質を含有するドラッグデリバリーシステムのための脂質ナノ粒子
KR20140111272A (ko) * 2011-12-12 2014-09-18 교와 핫꼬 기린 가부시키가이샤 양이온성 지질의 조합을 함유하는 지질 나노 입자
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
WO2015042369A2 (en) * 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
JP6836829B2 (ja) * 2014-08-04 2021-03-03 日東電工株式会社 核内受容体リガンドを含む免疫誘導促進用組成物及びワクチン医薬組成物
SI3325015T1 (sl) * 2015-07-20 2021-08-31 Zoetis Services Llc Liposomske pomožne sestavine
US12064480B2 (en) 2018-04-13 2024-08-20 Glaxosmithkline Biologicals Sa Immunigenic alpha-branched trehalose-diesters
KR20230002680A (ko) * 2020-04-15 2023-01-05 스태튼스 세룸 인스티튜트 병원성 감염의 예방 또는 조기 치료 용도의 리포솜 조성물
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN115068602B (zh) * 2022-08-22 2022-11-01 北京华诺泰生物医药科技有限公司 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
JP2714972B2 (ja) * 1988-02-02 1998-02-16 千葉製粉株式会社 リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤
JPH03249561A (ja) * 1990-02-28 1991-11-07 Toshiba Corp 免疫分析試薬
JPH0482824A (ja) * 1990-07-23 1992-03-16 Nippon Oil & Fats Co Ltd リポソーム及び水中油型エマルション
JPH0616688A (ja) * 1992-06-30 1994-01-25 Nippon Oil & Fats Co Ltd 脂肪酸糖エステル
JP3329554B2 (ja) * 1993-03-10 2002-09-30 千葉製粉株式会社 乾燥小胞体
JP3884488B2 (ja) * 1993-03-10 2007-02-21 千葉製粉株式会社 オリゴ糖脂質
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH0925287A (ja) * 1995-07-13 1997-01-28 Eisai Co Ltd 合成脂質
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2451091A1 (en) * 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University In Jerusale M A method for preparation of vesicles loaded with biological material and different uses thereof

Also Published As

Publication number Publication date
EP1765289B1 (en) 2008-09-03
EP1765289A2 (en) 2007-03-28
SI1765289T1 (sl) 2009-02-28
ES2315880T3 (es) 2009-04-01
CN1980638A (zh) 2007-06-13
JP4987704B2 (ja) 2012-07-25
PT1765289E (pt) 2008-12-05
ATE406874T1 (de) 2008-09-15
AU2005259685A1 (en) 2006-01-12
WO2006002642A2 (en) 2006-01-12
CA2572985A1 (en) 2006-01-12
ZA200701043B (en) 2007-12-27
DE602005009535D1 (de) 2008-10-16
KR101275837B1 (ko) 2013-06-18
JP2008505131A (ja) 2008-02-21
WO2006002642A3 (en) 2006-05-18
CA2572985C (en) 2014-04-22
BRPI0512757B1 (pt) 2021-04-06
AU2005259685B2 (en) 2010-04-08
BRPI0512757B8 (pt) 2021-05-25
BRPI0512757A (pt) 2008-04-08
KR20070051847A (ko) 2007-05-18
PL1765289T3 (pl) 2009-02-27
CN1980638B (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
ZA200701043B (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
RU2013114392A (ru) Маленькие липосомы для доставки кодирующей иммуноген рнк
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
EP4056198A3 (en) Outer membrane vesicles
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
NO20021431L (no) Intranasal influensavirus vaksine
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
DK1361890T3 (da) Influenzavaccineformuleringer til intradermal indgift
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
GB2386072A (en) Novel vaccine
WO2007024941A3 (en) Polyvalent vaccine
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2010019262A3 (en) Polyvalent vaccine
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
TW200510538A (en) Functionally reconstituted viral membranes containing adjuvant
AU2005332599A8 (en) Polyinosinic acid-polycytidylic acid-based adjuvant
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
GEAP202415627A (en) Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2008056174A3 (en) Novel compositions and uses thereof
WO2010053610A3 (en) Stable anthrax vaccine formulations
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren